About this trial
The proposed research aims to investigate the use of speech amplification devices as a potential treatment option for people with Parkinson's disease and related disorders who exhibit hypophonia, a voice disorder that affects over half of those with Parkinson's disease. By characterizing the acoustic and perceptual effects of speech amplification and identifying ways to optimize outcomes through talker- and device-specific enhancements, this project seeks to develop personalized, evidence-based treatment options for hypophonia. The current proposal will move this effort forward by systematically eliciting and modifying speech amplification device output that leverage both behavioral and technological approaches.
Eligibility criteria
Qualifiers
Dominant speakers of North American English
Have received a neurologist's diagnosis of Parkinson disease or parkinsonism (e.g., PSP/MSA/PSP)
Present with changes in their speech/voice
Disqualifiers
History of any other speech, language, or neurological concern other than Parkinson/parkinsonism.
Uncorrected hearing loss that exceeds a threshold of 40 dB HL in more than one ear (as per baseline screening audiometry) and/or use of a cochlear implant.
Trial design
Treatments tested in this trial
- Behavioral speech strategies + speech amplification
Treatment groups
Sponsors and collaborators
Michigan State University
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator